Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome

Size: px
Start display at page:

Download "Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome"

Transcription

1 British Journal of Obstetrics and Gynaecology January 1998, Vol. 105, pp Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome Khaldoun Sharif Lecturer, Manal Elgendy Research Fellow, Hany Lashen Research Fellow, Masoud Afnan Senior Lecturer Assisted Conception Unit, Birmingham Women j. Hospital Objective To examine the relative effect of basal follicle stimulating hormone (FSH) concentration and the woman s age on predicting the ovarian response to gonadotrophin stimulation, normal fertilisation rate and pregnancy rate in in vitro fertilisation (IVF) treatment following pituitary desensitisation. Design Descriptive cohort study. Participants Three hundred and forty-four women undergoing their first IVF cycle. Methods Basal (menstrual-day 3) FSH concentration was measured and the woman s age calculated before she underwent pituitary desensitisation followed by gonadotrophin ovarian stimulation and IVF treatment. Main outcome measures Cancellation rate due to poor ovarian response, total dose of gonadotrophin required to achieve follicular maturity, number of oocytes collected, normal fertilisation rate and pregnancy rate were compared between banded values of the variables studied. Results Increasing basal FSH concentration was associated significantly with increased cancellation rate, but increasing age was not. Both increasing basal FSH and age were associated significantly with increased total gonadotrophin dose, and reduced number of oocytes collected and pregnancy rate. Analysis of variance showed that the association for basal FSH with the number of oocytes was significant, independent of, and stronger than the effects of age. Logistic regression analysis showed that age, but not basal FSH, was independently associated with pregnancy rate. Neither basal FSH, nor age had significant association with normal fertilisation rate. Conclusion Basal FSH concentration is a better predictor of cancellation rate and of the number of oocytes collected in IVF treatment than age, but age is a stronger predictor of pregnancy rate. INTRODUCTION One of the factors that infertile couples take into consideration before deciding to embark on in vitro fertilisation treatment is the expected chances of achieving a pregnancy. Advancing age in the woman is well recognised to reduce natural fertility as well as the chances of pregnancy after all types of infertility treatment, including IVF1q2. As the menopause approaches, the chances of pregnancy decline. However, different women reach the menopause at different ages, and it is biologically plausible that the age-related decline in fertility may occur at different rates in different women. Age alone has limited predictive value, and it would be helpful, for both patient counselling and clinical management, to have another independent prognostic factor that can predict the true reproductive potential of each woman individually. One study3 has reported that women may Correspondence: Dr K. Sharif, Assisted Conception Unit, Birmingham Women s Hospital, Birmingham B15 2TG, UK. begin to have a subtle increase in their serum follicle stimulating hormone concentrations in their mid-thirties, coinciding with the time at which fertility begins to decline. Subsequently, another studf has shown that the earliest increase in FSH occurs in the early follicular phase. The use of early follicular phase (basal) serum FSH concentration was described by Scott et ~ 1 of. the ~ Jones institute, Norfolk, Virginia, USA, as a predictor of IVF outcome and was found by Toner et ~ 1 to. be ~ more predictive than age. However, Toner et al6 used pituitary desensitisation (which is now used in most IVF programmes) in only 38% of their study cycles and did not report on the analysis of those cycles separately. Furthermore, they transferred up to four embryos per woman; the maximum number allowed by law in the UK is three embryos, and many other countries have similar limits. Here again the analysis of their pregnancy rates (which are well recognised to correlate with the number of embryos transferred) may not be applicable in the UK. More recently, Cahill et al. reported on 0 RCOG 1998 British Journal of Obstetrics and Gynaecology 107

2 108 K. SHARIF ET AL. 171 IVF cycles following pituitary desensitisation and demonstrated the superior predictive value of basal FSH over age on ovarian response. However, they did not study the effect on cancellation rate (a major problem in poor responders), fertilisation rate or pregnancy rate (due to relatively small sample size). We report here on the analysis of the predictive value of basal FSH and age on cancellation rate, total dose of gonadotrophins, number of oocytes collected, normal fertilisation rate and pregnancy rate in 344 women undergoing their first IVF cycle after pituitary desensitisation. METHODS We studied 344 consecutive women undergoing their first IVF cycle at our unit between August 1994 and July Only first cycles were studied to avoid possible bias from experience of ovarian response in previous cycles. The indications for treatment were: tuba1 damage (40%), sperm dysfunction (35%) endometriosis (7%), unexplained infertility (13%) and ovulatory dysfunction (5%). Age was calculated as completed years on the day of starting ovarian stimulation. The serum FSH concentration was measured on day 3 of the period preceding the treatment cycle. Hormone assays Serum FSH concentration was measured using the Ciba Coring ACS FSH assay; a two-site chemiluminometric (sandwich) immunoassay using ACS 180 immunoanalyser (Ciba Coring Diagnostic Corporation, Massachusetts, USA). The assay was standardised against the World Health Organisation 2nd IRP 94/632 reference material. The in-house withm-batch coefficients of variation for this assay (determined by replicate analysis) were 456% at 5.13 IUL (n = 12), 4.06% at IUL (n = 12) and 4.92% at 47 IUL (n = 12). The betweenbatch corresponding values were 7.32% at 8.64 IUL (n = 127), 6.61% at IU/L (n = 52) and 9.53% at IUL (n = 107). In our laboratory the upper limit of normal (95th centile) for early follicular phase FSH was 10.8 IUL. Treatment protocol We followed protocols for desensitisation, ovarian stimulation, egg collection, gamete handling, embryo transfer and luteal support as described previou~ly~>~. Basically, gonadotrophin releasing hormone analogue (Nafarelin, Syntex, Berkshire, UK), 200 pg three times daily via nasal spray, was used for pituitary desensitisation (long protocol; starting from the mid-luteal phase of the previous cycle), followed by ovarian stimulation with human menopausal gonadotrophin (Metrodin HP, Serono, Welwyn Garden City, UK). We used a flat-dose protocol where a constant daily dose of gonadotrophin was administered according to the woman s age; three ampoules (75 IU each) for women aged 35 years or younger, four ampoules for women aged between 36 and 39 years, and six ampoules for women 40 years and older. Ovarian response was monitored using vaginal ultrasound scan. Human chorionic gonadotrophin (hcg) (Profasi, Serono, UK) 10,000 units were administered when there was a leading follicle of mm mean diameter and at least another three follicles over 14 mm. Twenty-eight women with three or fewer follicles > 14 mm mean diameter after 14 days of stimulation were considered to have poor response and counselled regarding cancelling their treatment cycle; all agreed to cancel treatment. Ultrasound directed oocyte retrieval was performed 36 hours after the hcg injection. Embryo transfer was performed hours following oocyte retrieval and progesterone (Gestone, Paines and Byrne, Surrey, UK) 100 mg/day (intramuscular) was given for luteal support. A urinary pregnancy test was performed two weeks following the embryo transfer and, if positive, a scan was performed at four weeks post-transfer. A clinical pregnancy was defined as that with fetal heart motion on ultrasound scan and a biochemical pregnancy as that where miscarriage has occurred before demonstrating fetal heart motion on scan. Analysis of results The end points studied were: cancellation rate for poor response, total dose of gonadotrophins used (calculated as the total number of ampoules used), number of oocytes collected, normal fertilisation rate (number of embryos with two pronuclei on day 1 following egg collection divided by the number of oocytes collected) and pregnancy rate per cycle. Dichotomous categorical variables were used to describe and analyse the data on cancellation rate and pregnancy rate. Continuous variables were used with the other end points. The independent variables studied were the woman s age and her basal FSH concentration. Continuous variables were examined for normalcy; logarithmic transformation was used where necessary to produce acceptable Gaussian distribution. The variables of age and basal FSH were banded for analysis into arbitrary interval groups. For age, there were four age groups: group years (n = 11 1, 32.3%); group 2 > years (n = 119, 34.6%); group 3 > 35 to < 40 years (n = 82,23.8%); and group years (n = 32, 9.3%). For FSH, there were three groups: FSH group IU/L (n = 39, 11.3%); FSH group 2 > 5.4 to < 10.8 IU/L (n = 273,79.4%); and FSH group IU/L (n = 32,9*3%).

3 ~~ ~ AGE AND FSH AS PREDICTORS OF IVF OUTCOME 109 Table 1. Age, basal serum follicle stimulating hormone (FSH), and number of eggs collected, embryos formed, and embryos transferred in the study population (n = 344). Median (range) Age (years) 33 (22-46) Basal FSH (IU/L) 7.25 (3-27) Total dose 33 (11-104) Eggs collected 9 (1-34) Fertilisation rate (%) 53 (0-100) Embryos formed 4 (0-23) Embryos transferred 3 (1-3) Interquartile range The effects of basal FSH concentration and age on the outcome variables were analysed using the two-sample t test and x2, as appropriate. In variables with which both FSH and age were found to have significant association, the relationship was further examined using a two-way analysis of variance (factorial ANOVA) employing the general linear model for continuous variables (total dose and number of oocytes) and logistic regression for binary variables (pregnancy). The software Stat- View (version 4.5, Abacus Concepts, California, USA) was used for analysis and statistical significance was assumed at P RESULTS All the 344 women had successful pituitary down regulation and started ovarian stimulation. Twenty-eight women (8.1%) had cancelled cycles because of poor ovarian response and did not proceed to egg collection. The remaining 316 women (9109%) had egg collection. Thirty-five women (10.2%) had total failure of fertilisation and the remaining 281 (81.7%) proceeded to embryo transfer. Of these, 178 (51.7%) had a negative pregnancy test and the remaining 103 had a positive test, yielding a 29.9% pregnancy rate per cycle started. Of these pregnancies 82 were clinical (2343% clinical pregnancy rate per cycle), 18 (5.2%) were biochemical, and three (047%) were ectopic. Table 1 shows the distribution of the age, basal FSH concentration, and the number of oocytes collected, embryos formed and embryos transferred in the study population. As shown in Fig. la, the cancellation rate in FSH groups 1 and 2 (normal values) were 5.1% and 54?%, respectively. In FSH group 3 it was 31-2%, considered a highly significant difference (P = ). On the other hand, as shown in Fig. 2a, there was no significant difference between the cancellation rate between different age groups (P = 0.98). Increased basal FSH concentration, as well as increased age, were significantly associated with increasing total gonadotrophin dose required (Figs lb and 2b), and a reduction in the number of oocytes Table 2. Two-way analysis of variance: probability of main effects. Age FSH AgexFSH Total dose < 0~0001 < 0~ No. of eggs collected collected (Figs lc and 2c). Of course, by virtue of our treatment protocol-where older women were given higher daily doses-there would be a significant increase in total dose with increased age, and no firm conclusions could be drawn from our study about the effect of age on the total gonadotrophin dose required. However, it is worth noting that this significant association (P = ) was also present between age groups one (I 30 years) and two (> 30 and I 35); women in both these groups received the same daily dose in our protocol, yet their total dose significantly increased with increasing age. Neither basal FSH concentration, nor the woman's age were significantly correlated with the normal fertilisation rate, as evident by the wide and overlapping confidence intervals in Figs Id and 2d. This applied whether all the couples were considered or only those with no male factor infertility (data not shown). In order to examine the effect of increased basal FSH concentration and age on pregnancy rate, these variables were analysed in a dichotomous categorical fashion; as normal and abnormal ( IUL) for FSH, and as I 35 or > 35 years for age. This was necessary to increase the power of the analysis due to the relatively small numbers. Both variables showed a statistically significant effect on pregnancy rate (Figs le and 2e). Thus, significant associations were found between both basal FSH concentration and age on one hand and the total dose and the number of oocytes collected on the other hand. Two-way analysis of variance was then employed in order to examine the independent (main) as well as the combined effect (interaction) of FSH and age (Table 2). The analysis of variance was applied about the age of 40 years and FSH of 10.8 Iu/L (both corresponding to the 95th centile). Both basal FSH concentration and age showed significant and independent associations with the total dose. Basal FSH, but not age, showed significant independent association with the number of oocytes collected. Logistic regression analysis showed that age (P = 0-01), but not basal FSH concentration (P = 0-l), was significantly associated with pregnancy rate; the significant association between FSH and pregnancy rate disappeared when controlled for age. DISCUSSION The results of this study have shown that age and basal FSH are predictive factors of the outcome of IVF

4 110 K. SHARIF J* ET AL 6o r v 8 30 c Q & 10 n I I I Normal Abnormal Fig. 1. Outcome measures (geometric means and 95% CI) related to FSH groups (group 1 I5.4 IU/L, group 2 > 5.4 to < 10.8 IU/L, group IU/L; groups 1 and 2 normal, group 3 abnormal). *P= , tp = (x2 test); $ P = 0.001, P= (two-sample 1 test). treatment following pituitary desensitisation. Their predictive values, however, seem to manifest in different ways. This may have several implications for counselling and clinical management, particularly for women younger than 35 years with abnormally high basal FSH concentration who would have been expected to perform differently on age basis alone. Cancellation rates for poor response were similar (7% to 8%) between different age groups, but differed significantly with basal FSH, rising from about 5% in women with concentration < 10.8 IU/L to over 30% in those with IU/L. To the best of our knowledge, this is the first reported study addressing this issue. Women with high basal FSH concentration should be counselled accordingly. The total gonadotrophin dose required to achieve follicular maturity increased significantly with increasing both age and basal FSH. As discussed above, part (but not all) of this increase with age could be explained by our treatment protocol. The increase with basal FSH, however, was highly significant and independent of the effect of age (Table 2). Drug cost forms a major component of the total cost of IVF treatment, and women with high basal FSH, particularly if older than 35 years, should be alerted to the high possibility of needing higher (more costly) total dose. Despite using higher total gonadotrophin dose with advancing age and increased basal FSH concentration, these two parameters were significantly associated with fewer oocytes retrieved. The effect of basal FSH concentration was independent of and more significant than that of age. Fewer oocytes will lead to fewer embryos available for either transfer or cryopreservation. Women with high basal FSH concentration should be warned that it is likely that they will have fewer oocytes collected and fewer (or perhaps no) embryos for cryopreservation.

5 AGE AND FSH AS PREDICTORS OF IVF OUTCOME c I I I I u) - a, 3 g Q u) - 40 m c ' a, L I I I I I T T T 1 I I I - * o o I I > Weeks Fig. 2. Outcome measures (geometric means and 95% CI) related to age groups (group 1 I 30 years, group 2 > years, group 3 > 35 to < 40 years, group years). *P = , tp = (two-sample t test);$ P = 0.01 (x2 test). Interestingly, the normal fertilisation rate did not differ significantly with either age or basal FSH concentration. This finding is in apparent contrast to that by Toner et al6 whose results indicated that both increased age and basal FSH were significantly associated with reduced number of fertilised oocytes. A possible explanation of this difference may lie in the fact that we have looked at the fertilisation rate while they have looked at the number of fertilised oocytes; fewer oocytes collected (which is the case with increased age and basal FSH) will lead to fewer embryos formed even in the presence of constant fertilisation rate. We have also found that the pregnancy rate per cycle decreased significantly with increasing both basal FSH concentration and age. Logistic regression analysis showed that the effect of basal FSH was not independent; increasing age alone could explain the associated decrease in pregnancy rate. This finding was in contrast to that by Toner et al. who found that basal FSH concentration was independent of, and stronger than age in significantly predicting pregnancy rate after IVF6. Their sample size (n = 1478) was much larger than ours and this may explain the apparently conflicting findings. An alternative explanation might be that all our patients had prior pituitary desensitisation compared with about one-third of their patients. Pituitary desensitisation may in some way modulate the effect of high basal FSH concentration on pregnancy rate. A larger study than ours is needed to clarify this point. We did not examine the association with miscarriage rate, clinical pregnancy rate or live birth rate. The numbers in our study were too small to make such analysis statistically meaningful.

6 112 K. SHARIF ET AL. Some statistical issues in our study deserve comment. When similar data have been handled in the literature previously, two statistical methods have been used. The first is linear regression analysis, where full advantage is taken of continuous data with out introducing arbitrary cut off points (e.g. different FSH and age group) as these may bias the results6. The second method used is to divide the continuous variables into banded values and analyse them as groups. We have elected to use the latter method in presenting these data for several reasons. First, clinicians usually think of, and work with, numerical results in a categorical fashion: normal or abnormal FSH (> 95th centile). Second, we believe that this method lends itself to more clarity when presented in graphs. Finally, we have also analysed our data by regression analysis (results not shown) and found similar results. The difference is in the form, not the substance. Currently it is not known whether the ovarian response and IVF outcome of women with high basal FSH concentration could be improved by altering the stimulation regimen (e.g. using the flare-up protocol or increasing the dose of gonadotrophin). The available data relate to high dose stimulation in those who have shown poor response in previous IVF cycles, regardless of their basal FSH concentrationlo. These data suggest that although the number of oocytes is significantly increased, the pregnancy rate remained very low lo. Currently some IVF clinicians would choose to extrapolate from those data and keep women with high basal FSH undergoing their first IVF cycle on the standard regimen, while others would increase their stimulation dose. The correct action is not known and perhaps the best action is to enrol these in a prospective randomised trial. Finally, a few practical points are worth mentioning in the context of measuring basal FSH concentration. First, we have measured FSH on menstrual day 3 to achieve consistency and comparability with previous studies. Nonetheless, it has been shown that the variability in FSH concentrations during menstrual days 2-5 is not significant, and it could be measured in practice on any of those days*. Second, basal FSH concentration does not have to be measured during the cycle immediately preceding the IVF treatment; the small intercycle variability is such that abnormally high levels in any previous cycle carry the same prognostic significancei2. The final point is to do with the upper limit of normal: it is very different in different assays (ranging from 9 to 22 IU/L)6,7. Clinicians should be aware of the normal limits in their local laboratories. CONCLUSION Our study has demonstrated that, in IVF treatment following pituitary desensitisation, basal FSH concentration is a better predictor of cancellation rate and of the number of oocytes collected than age, but age is a stronger predictor of pregnancy rate. The effect of basal FSH on pregnancy rate lost its significance when controlled for age. Many prognostic factors have been shown to correlate with the chances of achieving pregnancy after IVF treatment. These include the duration of infertility, previous pregnancy, the number and outcome of previous IVF attempts, and the woman s age. We recommend the addition of basal FSH concentration to those factors to individualise pre-treatment counselling for patients. Acknowledgement We would like to thank the clinical, nursing and laboratory staff at the Assisted Conception Unit for their assistance in collecting these data. References Federation CECOS, Schwartz D, Mayaux BA. Female fecundity as a function of age: results of artificial insemination in 2193 nulliparous women with azoospermic husbands. N Engl J Med 1982; 306: Templeton A, Moms JK, Parslow W. Factors that affect outcome of in-vitro fertilisation treatment. Lancet 1996; 348: Sherman BM, Korenman SG. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest 1975; 55: Lenton EA, Sexton L, Lee S, Cook ID. Progressive changes in LH and FSH and LH: FSH ratio in women throughout reproductive life. Maturitas 1988; Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks 2. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Ferfil Steril 1989; 51: Toner JP, Philput CB, Jones GS, Muasher SJ. Basal follicle stimulating hormone level is a better predictor of in vitro fertilisation performance than age. Feriil Steril1991; 55: Cahill DJ, Prosser CJ, Wardle PG, Ford WCL, Hull MGR. Relative influence of serum follicle stimulating hormone, age, and other factors on ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecoll994; 101: Sharif K, Afnan M, Lenton W. Mock embryo transfer with a full-bladder immediately before the real transfer for in-vitro fertilisation treatment: the Birmingham experience of 113 cases. Hum Reprod 1995; 10: Sharif K, Afnan M, Lenton W, Bilalis D, Hunjan M, Khalaf Y. Transmyometrial embryo transfer following difficult immediate mock transcervical transfer. Fertil Steril1996: 56: Land JA, Yarmolinskaya MI, Dumoulin JCM, Evers JLH. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril 1996; 65: Hansen LM, Batzer FR, Gutmann JN, Corson SL, Kelly MP, Gocial B. Evaluating ovarian reserve: follicle stimulating hormone and oestradiol variability during cycle days 2-5. Hum Reprod 1996; 11: Scott RT, Hofmann GE, Oehninger S, Muasher S3. Intercycle vanability of day 3 follicle-stimulating hormone levels and its effect on stimulation quality in in vitro fertilization. Fertil Steril 1990; 54: Received 26 February 1997 Returnedfor revision 4 July 1997 Accepted 23 July 1997

Martha Luna, M.D., a,b Lawrence Grunfeld, M.D., a,b Tanmoy Mukherjee, M.D., a,b Benjamin Sandler, M.D., a,b and Alan Barry Copperman, M.D.

Martha Luna, M.D., a,b Lawrence Grunfeld, M.D., a,b Tanmoy Mukherjee, M.D., a,b Benjamin Sandler, M.D., a,b and Alan Barry Copperman, M.D. ARTICLE IN PRESS Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify patients from attempting in vitro

More information

The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments Sykes D, Out H J, Palmer S J, van Loon J

The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments Sykes D, Out H J, Palmer S J, van Loon J The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments Sykes D, Out H J, Palmer S J, van Loon J Record Status This is a critical abstract of an economic evaluation that

More information

The objectives of this chapter are: To provide an understanding of the various stimulation protocols used in IVF To enable the student to understand

The objectives of this chapter are: To provide an understanding of the various stimulation protocols used in IVF To enable the student to understand 1 The objectives of this chapter are: To provide an understanding of the various stimulation protocols used in IVF To enable the student to understand the factors affecting the choice of protocol based

More information

SO, WHAT IS A POOR RESPONDER?

SO, WHAT IS A POOR RESPONDER? SO, WHAT IS A POOR RESPONDER? We now understand why ovarian reserve is important and how we assess it, but how is poor response defined? Unfortunately, there is no universally accepted definition for the

More information

FERTILITY AND AGE. Introduction. Fertility in the later 30's and 40's. Am I fertile?

FERTILITY AND AGE. Introduction. Fertility in the later 30's and 40's. Am I fertile? FERTILITY AND AGE Introduction Delaying pregnancy is a common choice for women in today's society. The number of women in their late 30s and 40s attempting pregnancy and having babies has increased in

More information

How do fertility drugs work?

How do fertility drugs work? How do fertility drugs work? Under normal circumstances, ovulation occurs once a month when a ripened egg which is ready to be fertilised is released from the ovaries. For couples who are trying to conceive,

More information

CONTROVERSY: VALUE OF THE DAY 3 FSH MEASUREMENT

CONTROVERSY: VALUE OF THE DAY 3 FSH MEASUREMENT CONTROVERSY: VALUE OF THE DAY 3 FSH MEASUREMENT FERTILITY AND STERILITY VOL. 81, NO. 6, JUNE 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free

More information

Symposium on RECENT ADVANCES IN ASSISTED REPRODUCTIVE TECHNOLOGY

Symposium on RECENT ADVANCES IN ASSISTED REPRODUCTIVE TECHNOLOGY Symposium on RECENT ADVANCES IN ASSISTED REPRODUCTIVE TECHNOLOGY Dr Niel Senewirathne Senior Consultant of Obstetrician & Gynaecologist De zoyza Maternity Hospita 1 ART - IVF & ICSI 2 Infertility No pregnancy

More information

Assisted Reproductive Technologies at IGO

Assisted Reproductive Technologies at IGO 9339 Genesee Avenue, Suite 220 San Diego, CA 92121 858 455 7520 Assisted Reproductive Technologies at IGO Although IGO no longer operates an IVF laboratory or program as such, we work closely with area

More information

The Outcome of Repeated In Vitro Fertilization-Embryo Transfer Based on the Endometrial Thickness

The Outcome of Repeated In Vitro Fertilization-Embryo Transfer Based on the Endometrial Thickness Bulletin of the Osaka Medical College 49 1, 2 5-9, 2003 5 Original Article The Outcome of Repeated In Vitro Fertilization-Embryo Transfer Based on the Endometrial Thickness Yoshiki YAMASHITA, Toshimitsu

More information

In-vitro fertilization in a spontaneous cycle: easy, cheap and realistic

In-vitro fertilization in a spontaneous cycle: easy, cheap and realistic Human Reproduction vol.15 no.2 pp.314 318, 2000 In-vitro fertilization in a spontaneous cycle: easy, cheap and realistic R.M.J.Janssens 1, C.B.Lambalk, J.P.W.Vermeiden, a decrease in endometrial receptivity

More information

AGE & FERTILITY: Effective Evaluation & Treatment I. LANE WONG, MD, FACOG. www.hopefertilitycenter.com www.hopeivf.com

AGE & FERTILITY: Effective Evaluation & Treatment I. LANE WONG, MD, FACOG. www.hopefertilitycenter.com www.hopeivf.com Page 1 of 6 AGE & FERTILITY: Effective Evaluation & Treatment I. LANE WONG, MD, FACOG. www.hopefertilitycenter.com www.hopeivf.com Age has a profound effect on female fertility. This is common knowledge,

More information

HOW IS OVARIAN RESERVE ASSESSED?

HOW IS OVARIAN RESERVE ASSESSED? HOW IS OVARIAN RESERVE ASSESSED? The majority of indicators we have to assess OR assess egg quantity rather than egg quality and these two do not always go hand in hand. No individual test is a perfect

More information

Reduced Ovarian Reserve Is there any hope for a bad egg?

Reduced Ovarian Reserve Is there any hope for a bad egg? Reduced Ovarian Reserve Is there any hope for a bad egg? Dr. Phil Boyle Galway Clinic, 19 th March 2014 For more information on Low AMH see www.napro.ie Anti Mullerian Hormone AMH levels are commonly measured

More information

Artificial insemination

Artificial insemination Artificial insemination What is involved? Artificial insemination is an assisted reproduction technique that consists of inserting laboratory-treated spermatozoa into the woman s uterus or cervical canal.

More information

How To Get A Refund On An Ivf Cycle

How To Get A Refund On An Ivf Cycle 100% IVF Refund Program Community Hospital North Clearvista Dr. N Dr. David Carnovale and Dr. Jeffrey Boldt, along with everyone at Community Reproductive Endocrinology, are committed to providing you

More information

OUR IVF/ICSI PROGRAMME

OUR IVF/ICSI PROGRAMME OUR IVF/ICSI PROGRAMME The Manzanera Fertility Clinic has designed a simple fertility programme that aims to be convenient for couples living outside of Spain while maximising your chances of success.

More information

Assisted reproductive technologies (ART) in Canada: 2011 results from the Canadian ART Register

Assisted reproductive technologies (ART) in Canada: 2011 results from the Canadian ART Register 1 Assisted reproductive technologies (ART) in Canada: 2011 results from the Canadian ART Register Joanne Gunby, M.Sc. CARTR Co-ordinator Email: gunbyj@mcmaster.ca Supported by the IVF Directors Group of

More information

Systematic review by: Dr. Ashraf Ahmed ElDaly, M.Sc., M.D.

Systematic review by: Dr. Ashraf Ahmed ElDaly, M.Sc., M.D. Role of luteinizing hormone supplementation in the follicular phase and pregnancy, during controlled ovarian hyperstimulation in in vitro fertilization Systematic review by: Dr. Ashraf Ahmed ElDaly, M.Sc.,

More information

50% Off Cycle 3 $ 9,900 $ 8,700 $ 7,500

50% Off Cycle 3 $ 9,900 $ 8,700 $ 7,500 Specialists In Reproductive Medicine & Surgery, P.A. www.dreamababy.com Fertility@DreamABaby.com Excellence, Experience & Ethics In Vitro Fertilization Price List (2015) We here at Specialists in Reproductive

More information

Fertility care for women diagnosed with cancer

Fertility care for women diagnosed with cancer Saint Mary s Hospital Department of Reproductive Medicine Fertility care for women diagnosed with cancer Information For Patients INF/DRM/NUR/16 V1/01/11/2013 1 2 Contents Page Overview 4 Our Service 4

More information

In - Vitro Fertilization Handbook

In - Vitro Fertilization Handbook In - Vitro Fertilization Handbook William F. Ziegler, D.O. Medical Director Scott Kratka, ELD, TS Embryology Laboratory Director Lauren F. Lucas, P.A.-C, M.S. Physician Assistant Frances Cerniak, R.N.

More information

One thousand initiated cycles of in vitro fertilization in women >40 years of age

One thousand initiated cycles of in vitro fertilization in women >40 years of age FERTILITY AND STERILITY VOL. 70, NO. 6, DECEMBER 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. One thousand initiated

More information

Clinical Policy Committee

Clinical Policy Committee Northern, Eastern and Western Devon Clinical Commissioning Group South Devon and Torbay Clinical Commissioning Group Clinical Policy Committee Commissioning policy: Assisted Conception Fertility assessment

More information

The Menstrual Cycle. Model 1: Ovarian Cycle follicular cells

The Menstrual Cycle. Model 1: Ovarian Cycle follicular cells The Menstrual Cycle REVIEW questions to complete before starting this POGIL activity 1. Gonads produce both gametes and sex steroid hormones. For the female, name the: A. gonads ovaries B. gametes oocyte/ovum/egg

More information

INFERTILITY/POLYCYSTIC OVARIAN SYNDROME. Ovulatory Dysfunction: Polycystic ovarian syndrome (PCOS)

INFERTILITY/POLYCYSTIC OVARIAN SYNDROME. Ovulatory Dysfunction: Polycystic ovarian syndrome (PCOS) Introduction Infertility is defined as the absence of pregnancy following 12 months of unprotected intercourse. Infertility may be caused by Ovulatory Dysfunction, Blocked Fallopian Tubes, Male Factor

More information

Fast Track to IVF. Objectives

Fast Track to IVF. Objectives Disclosure statement: Richard H. Reindollar, M.D. has no relevant financial relationships with any manufacturers of pharmaceuticals, laboratory supplies, or medical devices. Fast Track to IVF Richard H.

More information

Infertility Services Medical Policy For University of Vermont Medical Center and Central Vermont Medical Center employer groups

Infertility Services Medical Policy For University of Vermont Medical Center and Central Vermont Medical Center employer groups Infertility Services Medical Policy For University of Vermont Medical Center and Central Vermont Medical Center employer groups File name: Infertility Services File code: UM.REPRO.01 Last Review: 02/2016

More information

The Menstrual Cycle, Hormones and Fertility Treatment

The Menstrual Cycle, Hormones and Fertility Treatment The Menstrual Cycle, Hormones and Fertility Treatment How many of us understand how our monthly cycle works? Every 28 days (or thereabouts), between the ages of around 13 and 51, a woman will release a

More information

Acupuncture Treatment For Infertile Women Undergoing Intracytoplasmic Sperm injection

Acupuncture Treatment For Infertile Women Undergoing Intracytoplasmic Sperm injection Acupuncture Treatment For Infertile Women Undergoing Intracytoplasmic Sperm injection Sandra L. Emmons, MD Phillip Patton, MD Source: Medical Acupuncture, A Journal For Physicians By Physicians Spring

More information

Preimplantation Genetic Diagnosis (PGD) in Western Australia

Preimplantation Genetic Diagnosis (PGD) in Western Australia Preimplantation Genetic Diagnosis (PGD) in Western Australia Human somatic cells have 46 chromosomes each, made up of the 23 chromosomes provided by the egg and the sperm cell from each parent. Each chromosome

More information

Welcome to chapter 8. The following chapter is called "Monitoring IVF Cycle & Oocyte Retrieval". The author is Professor Jie Qiao.

Welcome to chapter 8. The following chapter is called Monitoring IVF Cycle & Oocyte Retrieval. The author is Professor Jie Qiao. Welcome to chapter 8. The following chapter is called "Monitoring IVF Cycle & Oocyte Retrieval". The author is Professor Jie Qiao. The learning objectives of this chapter are 2 fold. The first section

More information

Artificial insemination with donor sperm

Artificial insemination with donor sperm Artificial insemination with donor sperm Ref. 123 / 2009 Reproductive Medicine Unit Servicio de Medicina de la Reproducción Gran Vía Carlos III 71-75 08028 Barcelona Tel. (+34) 93 227 47 00 Fax. (+34)

More information

Aldo Campana 1, Denny Sakkas, Anne Stalberg, Patrizia Grace Bianchi, Isabelle Comte, Thierry Pache and Dilys Walker

Aldo Campana 1, Denny Sakkas, Anne Stalberg, Patrizia Grace Bianchi, Isabelle Comte, Thierry Pache and Dilys Walker Human Reproduction vol.11 no.4 pp.7-7, 1 Intrauterine insemination: evaluation of the results according to the woman's age, sperm quality, total sperm count per insemination and life table analysis Aldo

More information

Outline. Objective(s) Background. Methods. Results. Discussion. Questions

Outline. Objective(s) Background. Methods. Results. Discussion. Questions Outline Objective(s) Background Methods Results Discussion Questions Objectives To evaluate if psychological stress varies with the phase of in vitro fertilization treatment To determine if socio-demographic

More information

Drug Therapy Guidelines: Injectable Fertility Medications

Drug Therapy Guidelines: Injectable Fertility Medications Drug Therapy Guidelines: Injectable Fertility Medications Effective Date: 11/20/07 Committee Review Date: 7/12/00, 5/8/01, 1/15/02, 5/6/0, 12/16/0, 6/8/04, 12/16/05, 2/1/06, 10/15/06, 7/20/07, 11/5/07

More information

Reproduction and its Hormonal Control

Reproduction and its Hormonal Control Reproduction and its Hormonal Control Page 1 Reproduction and its Hormonal Control Different mammals have different patterns of reproduction Eg mammals, rats and mice can breed all year round, whereas

More information

Article. Laura Detti, MD, Frank D. Yelian, MD, PhD, Michael L. Kruger, MA, Michael P. Diamond, MD, Elizabeth E. Puscheck, MD

Article. Laura Detti, MD, Frank D. Yelian, MD, PhD, Michael L. Kruger, MA, Michael P. Diamond, MD, Elizabeth E. Puscheck, MD Article Endometrial Thickness Dynamics and Morphologic Characteristics During Pituitary Downregulation With Antagonists in Assisted Reproductive Technology Cycles Laura Detti, MD, Frank D. Yelian, MD,

More information

Elevated serum progesterone on the day of HCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome

Elevated serum progesterone on the day of HCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome Human Reproduction vol.14 no.3 pp.601 605, 1999 Elevated serum progesterone on the day of HCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome Nicola Doldi

More information

COVENTRY HEALTH CARE OF ILLINOIS, INC. COVENTRY HEALTH CARE OF MISSOURI, INC. Medical Management Policy and Procedure PROPRIETARY

COVENTRY HEALTH CARE OF ILLINOIS, INC. COVENTRY HEALTH CARE OF MISSOURI, INC. Medical Management Policy and Procedure PROPRIETARY COVENTRY HEALTH CARE OF ILLINOIS, INC. COVENTRY HEALTH CARE OF MISSOURI, INC. Medical Management Policy and Procedure PROPRIETARY Policy: Infertility Evaluation and Treatment Number: MM 1306 Date Effective:

More information

Final Version Two (Sept 2014) Eastern Cheshire Clinical Commissioning Group NHS Funded Treatment for Subfertility Policy

Final Version Two (Sept 2014) Eastern Cheshire Clinical Commissioning Group NHS Funded Treatment for Subfertility Policy Final Version Two (Sept 2014) Eastern Cheshire Clinical Commissioning Group NHS Funded Treatment for Subfertility Policy NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA Table of Contents 1.

More information

Clinical Reference Group Quality & Safety Committee Governing Body. Policy Screened

Clinical Reference Group Quality & Safety Committee Governing Body. Policy Screened Fertility Policy 1 SUMMARY This policy is intended to support individuals and couples who want to become parents but who have a possible pathological problem (physical or psychological) leading to them

More information

Commissioning Policy for In Vitro Fertilisation (IVF)/ Intracytoplasmic Sperm Injection (ICSI) within tertiary Infertility Services.

Commissioning Policy for In Vitro Fertilisation (IVF)/ Intracytoplasmic Sperm Injection (ICSI) within tertiary Infertility Services. East Midlands CCGs Commissioning Policy for In Vitro Fertilisation (IVF)/ Intracytoplasmic Sperm Injection (ICSI) within tertiary Infertility Services April 2014 CONTENTS Page 1. INTRODUCTION 3 2. GENERAL

More information

Timing is everything. Ovulation Tracking. Patient Information Booklet

Timing is everything. Ovulation Tracking. Patient Information Booklet Timing is everything Ovulation Tracking Patient Information Booklet Contents Getting pregnant naturally 3 Getting pregnant the basics 3 What is ovulation? 3 Menstrual cycle 4 When does ovulation take place?

More information

Tower Hamlets CCG Fertility policy

Tower Hamlets CCG Fertility policy Tower Hamlets CCG Fertility policy Approved December 2014 Introduction Tower Hamlets CCG is responsible for commissioning a range of health services including hospital, mental health and community services

More information

The relevant NICE Clinical Guidance 156, Fertility can be accessed here: http://www.nice.org.uk/guidance/cg156

The relevant NICE Clinical Guidance 156, Fertility can be accessed here: http://www.nice.org.uk/guidance/cg156 City and Hackney CCG Fertility policy Approved January 2015 Introduction City and Hackney CCG is responsible for commissioning a range of health services including hospital, mental health and community

More information

Age and Fertility. A Guide for Patients PATIENT INFORMATION SERIES

Age and Fertility. A Guide for Patients PATIENT INFORMATION SERIES Age and Fertility A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications

More information

Endometriosis, Fertility and Pregnancy

Endometriosis, Fertility and Pregnancy This leaflet covers endometriosis and fertility. It provides information for women who have been diagnosed with endometriosis who would like to know if and how this can affect their fertility, and for

More information

How to choose an IVF clinic and understand success rates: Questions to ask when choosing an IVF clinic.

How to choose an IVF clinic and understand success rates: Questions to ask when choosing an IVF clinic. Australia s National Infertility Network How to choose an IVF clinic and understand success rates: Questions to ask when choosing an IVF clinic. updated 26 05 2015 20 The information contained here is

More information

Topic: Male Factor Infertility

Topic: Male Factor Infertility Topic: Male Factor Infertility Topic Overview: Male Factor Infertility Comparisons of pregnancy rates at insemination based on total motile sperm counts from the 1999 and 21 World Health Organization (WHO)

More information

Standardising Access Criteria to NHS Fertility Treatment FOR COMMISSIONERS OF FERTILITY SERVICES

Standardising Access Criteria to NHS Fertility Treatment FOR COMMISSIONERS OF FERTILITY SERVICES Standardising Access Criteria to NHS Fertility Treatment FOR COMMISSIONERS OF FERTILITY SERVICES Status of the document This document offers guidance to help PCTs move towards more equitable provision

More information

Endocrinology of the Female Reproductive Axis

Endocrinology of the Female Reproductive Axis Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN

More information

East and North Hertfordshire CCG Fertility treatment and referral criteria for tertiary level assisted conception. December 2014

East and North Hertfordshire CCG Fertility treatment and referral criteria for tertiary level assisted conception. December 2014 East and North Hertfordshire CCG Fertility treatment and referral criteria for tertiary level assisted conception December 2014 1 1. Introduction This policy sets out the entitlement and service that will

More information

Consultations & other investigations

Consultations & other investigations Pricelist Please note as part of pre-treatment consultations, you may be required to have blood tests performed, the costs of which are not included in the treatment cycles. These costs are outlined below.

More information

30% Off Cycle 1. Possible Preliminary Discussions With Contract Negotiations

30% Off Cycle 1. Possible Preliminary Discussions With Contract Negotiations Specialists In Reproductive Medicine & Surgery, P.A. www.dreamababy.com Fertility@DreamABaby.com Excellence, Experience & Ethics Gestational Surrogacy Price List (2015) We here at Specialists in Reproductive

More information

Biology and Society Unit Five: Human Reproduction Topic Four: Assisted Reproductive Technologies (ART)

Biology and Society Unit Five: Human Reproduction Topic Four: Assisted Reproductive Technologies (ART) Biology and Society Unit Five: Human Reproduction Topic Four: Assisted Reproductive Technologies (ART) Carl Djerassi (1923 - ) Excerpt from Sex in an Age of Mechanical Reproduction by Carl Djerassi With

More information

Fertility-related choices. A decision aid for younger women with early breast cancer

Fertility-related choices. A decision aid for younger women with early breast cancer Fertility-related choices A decision aid for younger women with early breast cancer Fertility-related choices Section 1 About this booklet 1 Overview 3 Summary of fertility options 4 Section 2 Some background

More information

REPRODUCTIVE MEDICINE AND INFERTILITY ASSOCIATES Woodbury Medical Arts Building 2101 Woodwinds Drive Woodbury, MN 55125 (651) 222-6050

REPRODUCTIVE MEDICINE AND INFERTILITY ASSOCIATES Woodbury Medical Arts Building 2101 Woodwinds Drive Woodbury, MN 55125 (651) 222-6050 REPRODUCTIVE MEDICINE AND INFERTILITY ASSOCIATES Woodbury Medical Arts Building 2101 Woodwinds Drive Woodbury, MN 55125 (651) 222-6050 RECIPIENT COUPLE INFORMED CONSENT AND AUTHORIZATION FOR IN VITRO FERTILIZATION

More information

ASSISTED REPRODUCTIVE TECHNOLOGIES (ART)

ASSISTED REPRODUCTIVE TECHNOLOGIES (ART) ASSISTED REPRODUCTIVE TECHNOLOGIES (ART) Dr. Herve Lucas, MD, PhD, Biologist, Andrologist Dr. Taher Elbarbary, MD Gynecologist-Obstetrician Definitions of Assisted Reproductive Technologies Techniques

More information

ASSESSING DECISION TREE MODELS FOR CLINICAL IN VITRO FERTILIZATION DATA

ASSESSING DECISION TREE MODELS FOR CLINICAL IN VITRO FERTILIZATION DATA ASSESSING DECISION TREE MODELS FOR CLINICAL IN VITRO FERTILIZATION DATA Technical Report TR03 296 Dept. of Computer Science and Statistics University of Rhode Island LEAH PASSMORE 1, JULIE GOODSIDE 1,

More information

in vitro Fertilization (IVF)

in vitro Fertilization (IVF) Should an age limit be imposed on in vitro fertilization? Amanda Caster, Rong Hu, John Brothers II, and Barry Sexton Bioengineering and Bioinformatics Summer Institute 2005 University of Pittsburgh, Carnegie

More information

London Fertility Centre Price List

London Fertility Centre Price List London Fertility Centre Price List Fertility Testing Packages Standard Female fertility testing package AMH Ultrasound scan 15 minute doctor consultation to discuss your results Premium Female fertility

More information

NON MEDICARE FEES CANBERRA FERTILITY CENTRE VERSION JANUARY 2015 AM QWB 295

NON MEDICARE FEES CANBERRA FERTILITY CENTRE VERSION JANUARY 2015 AM QWB 295 NON MEDICARE FEES CANBERRA FERTILITY CENTRE VERSION JANUARY 2015 AM QWB 295 1 CANBERRA FERTILITY CENTRE Suite 9, Level 2, Peter Yorke Building, Calvary John James Hospital, 173 Strickland Crescent, DEAKIN

More information

Welcome to chapter 2. The following chapter is called "Indications For IVF". The author is Dr Kamini A. Rao.

Welcome to chapter 2. The following chapter is called Indications For IVF. The author is Dr Kamini A. Rao. Welcome to chapter 2. The following chapter is called "Indications For IVF". The author is Dr Kamini A. Rao. The indications for an IVF treatment have increased since the birth of the first IVF baby. The

More information

IN VITRO FERTILISATION IVF and ICSI

IN VITRO FERTILISATION IVF and ICSI IN VITRO FERTILISATION IVF and ICSI Page 1 of 7 WHAT ARE IVF and ICSI? IVF is short for in vitro fertilisation which means fertilisation outside the body. It usually involves stimulation of the ovaries

More information

University Hospitals Coventry and Warwickshire NHS Trust. Centre for Reproductive Medicine. We Care. We Achieve. We Innovate.

University Hospitals Coventry and Warwickshire NHS Trust. Centre for Reproductive Medicine. We Care. We Achieve. We Innovate. University Hospitals Coventry and Warwickshire NHS Trust Centre for Reproductive Medicine We Care. We Achieve. We Innovate. Introduction We were the first NHS Hospital in the West Midlands to set up a

More information

The following chapter is called "Follow-ups with a Positive or a Negative Pregnancy Test".

The following chapter is called Follow-ups with a Positive or a Negative Pregnancy Test. Slide 1 Welcome to chapter 7. The following chapter is called "Follow-ups with a Positive or a Negative Pregnancy Test". The author is Professor Pasquale Patrizio. Slide 2 This chapter has the following

More information

Recent Progress in In Vitro Fertilization and Intracytoplasmic Sperm Injection Technologies in Japan

Recent Progress in In Vitro Fertilization and Intracytoplasmic Sperm Injection Technologies in Japan Research and Reviews Recent Progress in In Vitro Fertilization and Intracytoplasmic Sperm Injection Technologies in Japan JMAJ 52(1): 29 33, 2009 Kaoru YANAGIDA* 1 Abstract The three basic pillars of fertility

More information

Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in Cases of Habitual Abortions

Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in Cases of Habitual Abortions Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in * (MBChB, FICMS, CABOG) **Sawsan Talib Salman (MBChB, FICMS, CABOG) ***Huda Khaleel Ibrahim (MBChB) Abstract Background: - Although

More information

1. AMOUNT OF FSH PRESENT

1. AMOUNT OF FSH PRESENT The Menstrual Cycle Name Date Period PRE-LAB 1. Write down three facts you know about the menstrual cycle. A. B. C. FOLLICULAR PHASE Within the ovaries are located many egg cells. Each egg is enclosed

More information

PREVENTION OF INFERTILITY SOURCE DOCUMENT THE IMPACT OF AGE ON FEMALE FERTILITY

PREVENTION OF INFERTILITY SOURCE DOCUMENT THE IMPACT OF AGE ON FEMALE FERTILITY PREVENTION OF INFERTILITY SOURCE DOCUMENT THE IMPACT OF AGE ON FEMALE FERTILITY BACKGROUND Over the past several decades, demographic and socioeconomic trends have resulted in an increase in the absolute

More information

OHTAC Recommendation. In Vitro Fertilization and Multiple Pregnancies

OHTAC Recommendation. In Vitro Fertilization and Multiple Pregnancies OHTAC Recommendation In Vitro Fertilization and Multiple Pregnancies October 19, 2006 The Ontario Health Technology Advisory Committee (OHTAC) met on October 19, 2006 and reviewed the health technology

More information

Project proposal. Reproductive tourism in India: A description of surrogate mothers and their offspring. Medical student Malene Tanderup Kristensen

Project proposal. Reproductive tourism in India: A description of surrogate mothers and their offspring. Medical student Malene Tanderup Kristensen Project proposal Reproductive tourism in India: A description of surrogate mothers and their offspring Background Medical student Malene Tanderup Kristensen Traditional surrogacy is defined as where the

More information

Clinical Study Comparison of Endocrine Profile and In Vitro Fertilization Outcome in Patients with PCOS, Ovulatory PCO, or Normal Ovaries

Clinical Study Comparison of Endocrine Profile and In Vitro Fertilization Outcome in Patients with PCOS, Ovulatory PCO, or Normal Ovaries International Endocrinology Volume 2012, Article ID 492803, 6 pages doi:10.1155/2012/492803 Clinical Study Comparison of Endocrine Profile and In Vitro Fertilization Outcome in Patients with PCOS, Ovulatory

More information

EFFECT OF INCREASED TESTOSTERONE LEVEL ON WOMAN S FERTILITY

EFFECT OF INCREASED TESTOSTERONE LEVEL ON WOMAN S FERTILITY 1 Nada Polyclinic, Po ega, Croatia 2 School of Medicine, University of Zagreb, Zagreb, Croatia Preliminary Communication Received: April 15, 2004 Accepted: June 16, 2004 EFFECT OF INCREASED TESTOSTERONE

More information

Jerry A. Sims, M.D., F.A.C.O.G. Reproductive Endocrinology & Infertility

Jerry A. Sims, M.D., F.A.C.O.G. Reproductive Endocrinology & Infertility Center of Reproductive Medicine 1015 Medical Center Blvd., Suite 2100 Webster, TX 77598 Phone (281)332-0073 FAX (281)557-5837 Jerry A. Sims, M.D., F.A.C.O.G. Reproductive Endocrinology & Infertility EDUCATION

More information

Aging and infertility in women

Aging and infertility in women Aging and infertility in women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama BACKGROUND Female fertility begins

More information

INFORMED CONSENT AND AUTHORIZATION FOR IN VITRO FERTILIZATION OF PREVIOUSLY CRYOPRESERVED OOCYTES

INFORMED CONSENT AND AUTHORIZATION FOR IN VITRO FERTILIZATION OF PREVIOUSLY CRYOPRESERVED OOCYTES INFORMED CONSENT AND AUTHORIZATION FOR IN VITRO FERTILIZATION OF PREVIOUSLY CRYOPRESERVED OOCYTES We, the undersigned, as patient and partner understand that we will be undergoing one or more procedures

More information

Management fertility sparing degli endometriomi Errico Zupi

Management fertility sparing degli endometriomi Errico Zupi Management fertility sparing degli endometriomi Errico Zupi Università Tor Vergata Roma Management of endometrioma Pain Infertility Surgical treatment Medical treatment Infertility clinic Both medical

More information

Assisted reproductive technology in Australia and New Zealand 2010

Assisted reproductive technology in Australia and New Zealand 2010 Assisted reproductive technology in Australia and New Zealand 2010 ASSISTED REPRODUCTION SERIES Number 16 Assisted reproductive technology in Australia and New Zealand 2010 Alan Macaldowie Yueping A Wang

More information

Methods for improvement of the success rate of artificial insemination with donor semen

Methods for improvement of the success rate of artificial insemination with donor semen INTERNATIONAL JOURNAL OFANDROLOGY 9 (1986) 14-2 Departments of Internul Medicine and Obstetrics, State University Hospital, Gent, Belgium Methods for improvement of the success rate of artificial insemination

More information

Lesbian Pregnancy: Donor Insemination

Lesbian Pregnancy: Donor Insemination Lesbian Pregnancy: Donor Insemination (Based on an article originally published in the American Fertility Association 2010 National Fertility and Adoption Directory. Much of this information will also

More information

Evaluation of endometrial receptivity during in-vitro fertilization using three-dimensional power Doppler ultrasound

Evaluation of endometrial receptivity during in-vitro fertilization using three-dimensional power Doppler ultrasound Ultrasound Obstet Gynecol 2005; 26: 765 769 Published online 4 November 2005 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.2628 Evaluation of endometrial receptivity during in-vitro

More information

In Vitro Fertilization (IVF) Page 1 of 11

In Vitro Fertilization (IVF) Page 1 of 11 In Vitro Fertilization (IVF) Page 1 of 11 This document is a part of your informed consent process. Both partners should read the entire document carefully. In vitro fertilization (IVF) is a treatment

More information

Clinical Study Comparison of IVF Outcomes between Minimal Stimulation and High-Dose Stimulation for Patients with Poor Ovarian Reserve

Clinical Study Comparison of IVF Outcomes between Minimal Stimulation and High-Dose Stimulation for Patients with Poor Ovarian Reserve International Reproductive Medicine, Article ID 581451, 5 pages http://dx.doi.org/10.1155/2014/581451 Clinical Study Comparison of IVF Outcomes between Minimal Stimulation and High-Dose Stimulation for

More information

Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve

Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve FERTILITY AND STERILITY VOL. 77, NO. 2, FEBRUARY 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Predictors of poor

More information

BUTTE COUNTY PUBLIC HEALTH DEPARTMENT POLICY & PROCEDURE

BUTTE COUNTY PUBLIC HEALTH DEPARTMENT POLICY & PROCEDURE BUTTE COUNTY PUBLIC HEALTH DEPARTMENT POLICY & PROCEDURE SUBJECT: Pregnancy Testing and Counseling Protocol P&P # APPROVED BY: EFFECTIVE DATE: Mark Lundberg MD Health Officer REVISION DATE: 2/20/2010 Phyllis

More information

In vitro fertilisation (IVF) & intra-cytoplasmic sperm injection (ICSI)

In vitro fertilisation (IVF) & intra-cytoplasmic sperm injection (ICSI) In vitro fertilisation (IVF) & intra-cytoplasmic sperm injection (ICSI) Inside: The stages of ivf & icsi What to expect from treatment Coping with stress Part of the Pathways to Parenthood booklet series

More information

Risks and complications of assisted conception

Risks and complications of assisted conception Risks and complications of assisted conception August 005 Richard Kennedy British Fertility Society Factsheet www.fertility.org.uk No medical treatment is entirely free from risk and infertility treatment

More information

SPONTANEOUS AND PHARMACOLOGICALLY INDUCED REMISSIONS IN PATIENTS WITH PREMATURE OVARIAN FAILURE

SPONTANEOUS AND PHARMACOLOGICALLY INDUCED REMISSIONS IN PATIENTS WITH PREMATURE OVARIAN FAILURE SPONTANEOUS AND PHARMACOLOGICALLY INDUCED REMISSIONS IN PATIENTS WITH PREMATURE OVARIAN FAILURE David Kreiner, M. D. * Kathleen Droesch, M.D. Daniel Navot, M.D. Richard Scott, M.D. Zev Rosenwaks, M.D.

More information

IVF MONEY-BACK PLAN IN PARTNERSHIP WITH

IVF MONEY-BACK PLAN IN PARTNERSHIP WITH IVF MONEY-BACK PLAN IN PARTNERSHIP WITH Programmes Refund Programme Up to 3 fresh cycles of IVF/ICSI and all frozen embryo transfers Available to women under 40 years old Medical Review required for all

More information

Authorized By: Holly C. Bakke, Commissioner, Department of Banking and Insurance.

Authorized By: Holly C. Bakke, Commissioner, Department of Banking and Insurance. INSURANCE DIVISION OF INSURANCE Actuarial Services Benefit Standards for Infertility Coverage Proposed New Rules: N.J.A.C. 11:4-54 Authorized By: Holly C. Bakke, Commissioner, Department of Banking and

More information

In vitro fertilization for Orthodox Jewish couples: antagonist cycle modifications allowing for mikveh attendance before oocyte retrieval

In vitro fertilization for Orthodox Jewish couples: antagonist cycle modifications allowing for mikveh attendance before oocyte retrieval In vitro fertilization for Orthodox Jewish couples: antagonist cycle modifications allowing for mikveh attendance before oocyte retrieval David E. Reichman, M.D., Anate Aelion Brauer, M.D., Dan Goldschlag,

More information

The IUI procedure Who should consider an IUI IUI success rates IUI cost What to consider if IUI is unsuccessful. The IUI procedure:

The IUI procedure Who should consider an IUI IUI success rates IUI cost What to consider if IUI is unsuccessful. The IUI procedure: A Complete Guide to understanding IUI (intrauterine insemination) and artificial insemination (Eric Daiter, MD Board Certified in Reproductive Endocrinology and Infertility) The IUI procedure Who should

More information

Director, IVF Program, Division of Reproductive Endocrinology & Infertility

Director, IVF Program, Division of Reproductive Endocrinology & Infertility Director, IVF Program, Division of Reproductive Endocrinology & Infertility Date: January 17, 2006 To: From: RE: All IVF candidates Chief, Reproductive Endocrinology & Infertility Criteria for IVF program

More information

Effect of pretreatment with transdermal testosterone on poor ovarian responders undergoing IVF/ICSI: A meta-analysis

Effect of pretreatment with transdermal testosterone on poor ovarian responders undergoing IVF/ICSI: A meta-analysis EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 187-194, 2014 Effect of pretreatment with transdermal testosterone on poor ovarian responders undergoing IVF/ICSI: A meta-analysis SHAN LUO, SHANGWEI LI, XIAOHONG

More information

Anatomy and Physiology of Human Reproduction. Module 10a

Anatomy and Physiology of Human Reproduction. Module 10a This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Illinois Insurance Facts Illinois Department of Financial and Professional Regulation Division of Insurance

Illinois Insurance Facts Illinois Department of Financial and Professional Regulation Division of Insurance Illinois Insurance Facts Illinois Department of Financial and Professional Regulation Division of Insurance Insurance Coverage for Infertility Treatment Revised November 2004 Infertility is a condition

More information

Patient Information: Endometriosis Disease Process and Treatment

Patient Information: Endometriosis Disease Process and Treatment 1 William N. Burns, M. D. Associate Professor Department of Obstetrics & Gynecology Joan C. Edwards School of Medicine Marshall University Huntington, West Virginia, USA Patient Information: Endometriosis

More information

Carol Ludowese, MS, CGC Certified Genetic Counselor HDSA Center of Excellence at Hennepin County Medical Center Minneapolis, Minnesota

Carol Ludowese, MS, CGC Certified Genetic Counselor HDSA Center of Excellence at Hennepin County Medical Center Minneapolis, Minnesota Carol Ludowese, MS, CGC Certified Genetic Counselor HDSA Center of Excellence at Hennepin County Medical Center Minneapolis, Minnesota The information provided by speakers in workshops, forums, sharing/networking

More information